.png)
number of participants: 613
EFFICACY
52 a 69%
research rigor
08/2000
Pain relief within two hours occurred in 52%–69% of patients treated with any dose of naratriptan, 60% of patients treated with sumatriptan, and was significantly superior to placebo (31%).
Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study. Clinical Therapeutics, [S.L.], v. 22, n. 8, p. 970-980, ago. 2000. Elsevier BV.
HAVANKA, Hannele; DAHLÖF, Carl; POP, Paul H.M.; DIENER, Hans-Christoph; WINTER, Paul; WHITEHOUSE, Helen; HASSANI, Habib.
DATE
EFFICACY
60 a 68%
Research rigor
number of participants: 586
DATE
12/1997
Pain relief within 4 hours occurred in 60–68% of treated patients and was significantly superior to placebo in both studies. The efficacy on associated symptoms (nausea, phonophobia, and photophobia) was also significantly greater than placebo in both studies.
MATHEW, Ninan T.; ASGHARNEJAD, Mahnaz; PEYKAMIAN, Margaret; LAURENZA, Antonio.
Naratriptan is effective and well tolerated in the acute treatment of migraine. Neurology, [S.L.], v. 49, n. 6, p. 1485-1490, dez. 1997. Ovid Technologies (Wolters Kluwer Health).
INDICATION
CHILDREN
EFFICACY
60 a 68%
Research rigor
Number of participants: 850
DATE
06/1999
Naratriptan has recently been approved for the acute oral treatment of migraine.
In two Phase III trials comparing naratriptan to placebo, four-hour relief was achieved in 60% and 68% of patients using the 2.5 mg dose, with headache recurrence within 24 hours occurring in 27% and 28% of patients, respectively.
2.5 mg A search of MEDLINE was conducted for the period from January 1990 to June 1998. Naratriptan has recently been approved for the acute oral treatment of migraine. In two Phase III trials comparing naratriptan to placebo, four-hour pain relief was achieved in 60% and 68% of patients using the 2.5 mg dose, with headache recurrence within 24 hours in 27% and 28% of patients.
SEVCO:01035
D A Dulli . Naratriptano: uma alternativa para enxaqueca